{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:34:47Z","timestamp":1792611287159,"version":"4.5.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","academicpedsjnl.net","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Academic Pediatrics"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.acap.2017.09.014","type":"journal-article","created":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T04:11:38Z","timestamp":1519877498000},"page":"S3-S10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":195,"special_numbering":"S","title":["Ten Years of Human Papillomavirus Vaccination in the United States"],"prefix":"10.1016","volume":"18","author":[{"given":"Lauri E.","family":"Markowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne","family":"Gee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrell","family":"Chesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Stokley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 5","key":"10.1016\/j.acap.2017.09.014_bib1","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30","author":"Forman","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.acap.2017.09.014_bib2","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.acap.2017.09.014_bib3","doi-asserted-by":"crossref","first-page":"djv086","DOI":"10.1093\/jnci\/djv086","article-title":"US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines","volume":"107","author":"Saraiya","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 5","key":"10.1016\/j.acap.2017.09.014_bib4","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.acap.2017.09.014_bib5","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Markowitz","year":"2014","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.acap.2017.09.014_bib6","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.acap.2017.09.014_bib7","first-page":"1","article-title":"Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Markowitz","year":"2007","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.acap.2017.09.014_bib8","first-page":"1","article-title":"General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) (errata in: 2006;55:1303, Pediatrics 2007;119:1008 and 2007;56:256)","volume":"55","author":"Kroger","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.acap.2017.09.014_bib9","first-page":"626","article-title":"FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.acap.2017.09.014_bib10","first-page":"630","article-title":"FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.acap.2017.09.014_bib11","first-page":"1705","article-title":"Recommendations on the use of quadrivalent human papillomavirus vaccine in males - Advisory Committee on Immunization Practices (ACIP), 2011","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.acap.2017.09.014_bib12","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the Advisory Committee on Immunization Practices","volume":"65","author":"Meites","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.acap.2017.09.014_bib13","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acap.2017.09.014_bib14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1071\/SH16067","article-title":"Human papillomavirus vaccination in men who have sex with men - what will be required by 2020 for the same dramatic changes seen in heterosexuals","volume":"14","author":"Fairley","year":"2017","journal-title":"Sex Health"},{"key":"10.1016\/j.acap.2017.09.014_bib15","doi-asserted-by":"crossref","first-page":"b3884","DOI":"10.1136\/bmj.b3884","article-title":"Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States","volume":"339","author":"Kim","year":"2009","journal-title":"Br Med J"},{"key":"10.1016\/j.acap.2017.09.014_bib16","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1016\/j.vaccine.2011.07.096","article-title":"The cost-effectiveness of male HPV vaccination in the United States","volume":"29","author":"Chesson","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.acap.2017.09.014_bib17","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1016\/j.vaccine.2010.08.030","article-title":"Impact of vaccinating boys and men against HPV in the United States","volume":"28","author":"Elbasha","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.acap.2017.09.014_bib18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acap.2017.09.014_bib19","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2016.17615","article-title":"Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women","volume":"316","author":"Iversen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.acap.2017.09.014_bib20","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.2016.16393","article-title":"Two vs three doses of human papillomavirus vaccine: new policy for the second decade of the vaccination program","volume":"316","author":"Markowitz","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.acap.2017.09.014_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3201\/eid0901.020168","article-title":"Cost-effectiveness of a potential vaccine for human papillomavirus","volume":"9","author":"Sanders","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.acap.2017.09.014_bib22","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3201\/eid1011.040222","article-title":"Evaluating human papillomavirus vaccination programs","volume":"10","author":"Taira","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.acap.2017.09.014_bib23","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/jnci\/djh104","article-title":"Projected clinical benefits and cost-effectiveness of a human papillomavirus 16\/18 vaccine","volume":"96","author":"Goldie","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.acap.2017.09.014_bib24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus vaccination strategies","volume":"13","author":"Elbasha","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.acap.2017.09.014_bib25","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMsa0707052","article-title":"Health and economic implications of HPV vaccination in the United States","volume":"359","author":"Kim","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acap.2017.09.014_bib26","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3201\/eid1402.070499","article-title":"Cost-effectiveness of human papillomavirus vaccination in the United States","volume":"14","author":"Chesson","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.acap.2017.09.014_bib27","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S1473-3099(10)70219-X","article-title":"Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis","volume":"10","author":"Kim","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.acap.2017.09.014_bib28","doi-asserted-by":"crossref","first-page":"djv282","DOI":"10.1093\/jnci\/djv282","article-title":"Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States","volume":"108","author":"Brisson","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.acap.2017.09.014_bib29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/infdis\/jiw227","article-title":"Comparison of 2-dose and 3-dose 9-valent human papillomavirus vaccine schedules in the United States: a cost-effectiveness analysis","volume":"214","author":"Laprise","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.acap.2017.09.014_bib30","author":"CDC"},{"key":"10.1016\/j.acap.2017.09.014_bib31","doi-asserted-by":"crossref","first-page":"874","DOI":"10.15585\/mmwr.mm6633a2","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2016","volume":"66","author":"Walker","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.acap.2017.09.014_bib32","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.15585\/mmwr.mm6442a1","article-title":"Human papillomavirus vaccination coverage among female adolescents in managed care plans - United States, 2013","volume":"64","author":"Ng","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.acap.2017.09.014_bib33","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1177\/0009922815616245","article-title":"Human papillomavirus vaccination coverage among girls before 13 years: a birth year cohort analysis of the National Immunization Survey-Teen, 2008-2013","volume":"55","author":"Jeyarajah","year":"2016","journal-title":"Clin Pediatr"},{"key":"10.1016\/j.acap.2017.09.014_bib34","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1056\/NEJMc071068","article-title":"Mandating HPV vaccination\u2013private rights, public good","volume":"356","author":"Stewart","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acap.2017.09.014_bib35","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2105\/AJPH.2011.300576","article-title":"Pharmaceutical companies\u2019 role in state vaccination policymaking: the case of human papillomavirus vaccination","volume":"102","author":"Mello","year":"2012","journal-title":"Am J Public Health"},{"key":"10.1016\/j.acap.2017.09.014_bib36","doi-asserted-by":"crossref","first-page":"e20161414","DOI":"10.1542\/peds.2016-1414","article-title":"School entry requirements and coverage of nontargeted adolescent vaccines","volume":"138","author":"Moss","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.acap.2017.09.014_bib37","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1080\/21645515.2016.1161460","article-title":"Current initiatives to protect Rhode Island adolescents through increasing HPV vaccination","volume":"12","author":"Washburn","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.acap.2017.09.014_bib38","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1080\/21645515.2015.1125055","article-title":"Interventions to increase HPV vaccination coverage: a systematic review","volume":"12","author":"Smulian","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.acap.2017.09.014_bib39","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/jamapediatrics.2013.2752","article-title":"Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature","volume":"168","author":"Holman","year":"2014","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.acap.2017.09.014_bib40","doi-asserted-by":"crossref","first-page":"e20152488","DOI":"10.1542\/peds.2015-2488","article-title":"Primary care physicians\u2019 perspectives about HPV vaccine","volume":"137","author":"Allison","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.acap.2017.09.014_bib41","author":"CDC"},{"key":"10.1016\/j.acap.2017.09.014_bib42","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1080\/21645515.2016.1157673","article-title":"Comparing human papillomavirus vaccine knowledge and intentions among parents of boys and girls","volume":"12","author":"Lindley","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.acap.2017.09.014_bib43","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.vaccine.2013.11.076","article-title":"Parent and provider perspectives on immunization: are providers overestimating parental concerns?","volume":"32","author":"Healy","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.acap.2017.09.014_bib44","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1080\/21645515.2016.1168952","article-title":"Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States","volume":"12","author":"Gee","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.acap.2017.09.014_bib45","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4161\/hv.5.5.7211","article-title":"Safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials","volume":"5","author":"Descamps","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.acap.2017.09.014_bib46","doi-asserted-by":"crossref","first-page":"e20154387","DOI":"10.1542\/peds.2015-4387","article-title":"Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials","volume":"138","author":"Moreira","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.acap.2017.09.014_bib47","series-title":"Guardasil (human papillomavirus quadrivalent [types 6, 11, 16, and 18] vaccine, recombinant) Suspension for intramuscular injection [prescribing information]","year":"2011"},{"key":"10.1016\/j.acap.2017.09.014_bib48","unstructured":"Cervarix (human papillomavirus bivalent [types 16, 18] vaccine, recombinant) Suspension for intramuscular injection [prescribing information]. Rixensart, Belgium; GlaxoSmithKline."},{"key":"10.1016\/j.acap.2017.09.014_bib49","first-page":"457","article-title":"Syncope after vaccination\u2013United States, January 2005-July 2007","volume":"57","author":"Centers for Disease Control and Prevention (CDC)","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.acap.2017.09.014_bib50","author":"CDC"},{"key":"10.1016\/j.acap.2017.09.014_bib51","first-page":"620","article-title":"Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014\u2013United States","volume":"63","author":"Stokley","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.acap.2017.09.014_bib52","first-page":"393","article-title":"Meeting of the Global Advisory Committee on Vaccine Safety, 7-8 June 2017","volume":"92","author":"World Health Organization","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.acap.2017.09.014_bib53","series-title":"Adverse effects of vaccines: Evidence and causality","year":"2012"},{"key":"10.1016\/j.acap.2017.09.014_bib54","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1080\/21645515.2015.1109169","article-title":"Understanding the role of the news media in HPV vaccine uptake in the United States: synthesis and commentary","volume":"12","author":"Gollust","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.acap.2017.09.014_bib56","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1080\/10410236.2011.610258","article-title":"When vaccines go viral: an analysis of HPV vaccine coverage on YouTube","volume":"27","author":"Briones","year":"2012","journal-title":"Health Commun"},{"key":"10.1016\/j.acap.2017.09.014_bib57","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1542\/peds.2012-1516","article-title":"Sexual activity-related outcomes after human papillomavirus vaccination of 11- to 12-year-olds","volume":"130","author":"Bednarczyk","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.acap.2017.09.014_bib58","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1016\/j.vaccine.2014.07.025","article-title":"Human papillomavirus (HPV) vaccination and subsequent sexual behaviour: evidence from a large survey of Nordic women","volume":"32","author":"Hansen","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.acap.2017.09.014_bib59","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/infdis\/jit192","article-title":"Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010","volume":"208","author":"Markowitz","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.acap.2017.09.014_bib60","doi-asserted-by":"crossref","first-page":"e20151968","DOI":"10.1542\/peds.2015-1968","article-title":"Prevalence of HPV after introduction of the vaccination program in the United States","volume":"137","author":"Markowitz","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.acap.2017.09.014_bib61","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/infdis\/jix244","article-title":"Prevalence of human papillomavirus among females after vaccine introduction \u2013 National Health and Nutrition Examination Survey, United States, 2003-2014","volume":"216","author":"Oliver","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.acap.2017.09.014_bib62","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/infdis\/jiv342","article-title":"Reduction in human papillomavirus vaccine type prevalence among young women screened for cervical cancer in an integrated US healthcare delivery system in 2007 and 2012","volume":"212","author":"Dunne","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.acap.2017.09.014_bib63","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1542\/peds.2011-3587","article-title":"Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction","volume":"130","author":"Kahn","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.acap.2017.09.014_bib64","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/cid\/ciw533","article-title":"Substantial decline in vaccine-type human papillomavirus (HPV) among vaccinated young women during the first 8 years after HPV vaccine introduction in a community","volume":"63","author":"Kahn","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.acap.2017.09.014_bib65","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.2105\/AJPH.2012.301182","article-title":"Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination","volume":"103","author":"Flagg","year":"2013","journal-title":"Am J Public Health"},{"key":"10.1016\/j.acap.2017.09.014_bib66","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/OLQ.0000000000000369","article-title":"Trends in male and female genital warts among adolescents in a safety-net health care system 2004-2013: correlation with introduction of female and male human papillomavirus vaccination","volume":"42","author":"Perkins","year":"2015","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.acap.2017.09.014_bib67","unstructured":"Gargano JW, Johnson M, Griffin MR, et\u00a0al. Trends in high-grade cervical lesions and cervical cancer screening in five states, 2008\u20132014. Presented at the 31st International Papillomavirus Conference; February 28-March 4, 2017; Cape Town, South Africa."},{"key":"10.1016\/j.acap.2017.09.014_bib68","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jamaoncol.2016.3609","article-title":"Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era","volume":"3","author":"Benard","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.acap.2017.09.014_bib69","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2105\/AJPH.2016.303472","article-title":"Ecological association of human papillomavirus vaccination with cervical dysplasia prevalence in the United States, 2007-2014","volume":"106","author":"Flagg","year":"2016","journal-title":"Am J Public Health"},{"key":"10.1016\/j.acap.2017.09.014_bib70","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.acap.2017.09.014_bib71","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.3201\/eid2210.160675","article-title":"Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes","volume":"22","author":"Mesher","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.acap.2017.09.014_bib72","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1309\/AJCPTGD94EVRSJCG","article-title":"American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer","volume":"137","author":"Saslow","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.acap.2017.09.014_bib73","doi-asserted-by":"crossref","first-page":"880","DOI":"10.7326\/0003-4819-156-12-201206190-00424","article-title":"Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement","volume":"156","author":"Moyer","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.acap.2017.09.014_bib74","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1002\/cncr.29266","article-title":"Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States","volume":"121","author":"Hariri","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.acap.2017.09.014_bib75","article-title":"Healthy People 2020","year":"2011","journal-title":"Immunization and infectious disease. Healthy People 2020. Immunization and Infectious Disease"}],"container-title":["Academic Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876285917304941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876285917304941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T15:51:24Z","timestamp":1535039484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876285917304941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1876285917304941"],"URL":"https:\/\/doi.org\/10.1016\/j.acap.2017.09.014","relation":{},"ISSN":["1876-2859"],"issn-type":[{"value":"1876-2859","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ten Years of Human Papillomavirus Vaccination in the United States","name":"articletitle","label":"Article Title"},{"value":"Academic Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acap.2017.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of Academic Pediatric Association","name":"copyright","label":"Copyright"}]}}